A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
- Conditions
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03816176
- Locations
- 🇪🇸
Site ES34002, Barcelona, Spain
🇪🇸Site ES34001, Madrid, Spain
🇪🇸Site ES34003, Madrid, Spain
A Study of ASP1951 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT03799003
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03760081
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Abramson Cancer Center University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03755713
- Locations
- 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Sean N Parker Center for Allergy & Asthma Research, LPCH El Camino Hospital, Mountain View, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03730012
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03698305
- Locations
- 🇺🇸
Covance CRU, Daytona Beach, Daytona Beach, Florida, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT03682484
- Locations
- 🇺🇸
Parexel - Baltimore, Baltimore, Maryland, United States
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 507
- Registration Number
- NCT03653507
- Locations
- 🇺🇸
Parkland Hospital, Dallas, Texas, United States
🇺🇸University of Kansas Cancer Center and Medical Pavilion, Fairway, Kansas, United States
🇵🇹Site PT35109, Braga, Portugal
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT03565445
- Locations
- 🇺🇸
UPMC- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Synergy East, Lemon Grove, California, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States